1. Background {#sec0005}
=============

Community-acquired pneumonia (CAP) among children under-5 years old causes a major burden to health care systems worldwide \[[@bib0005]\], where it is estimated the occurrence of 156 million new CAP cases annually in this age range \[[@bib0010]\]. Therefore, effective measures to control this condition are demanded \[[@bib0015]\].

The implementation of bacteria-related vaccines, such as pneumococcal and *Haemophilus influenzae* type b conjugate vaccines, in association with the recent widespread availability of nucleic acid amplification techniques, such as real-time polymerase chain reaction (RT-PCR), had a great impact in the estimation of the proportion of respiratory virus infection in patients with acute respiratory illness \[[@bib0020]\]. However, the role of respiratory viruses remains unclear among cases with non-severe CAP, which raises concern \[[@bib0025]\]. Moreover, information on respiratory viruses in non-severe CAP cases is scarce.

2. Objectives {#sec0010}
=============

We estimated the frequency of the detection of respiratory viruses among cases with non-severe CAP, compared the frequency of each respiratory virus among children with sole virus detection or co-detection, and assessed age and disease duration distribution between children with or without each respiratory virus.

3. Study design {#sec0015}
===============

This study was conducted in accordance with the Declaration of Helsinki and national and institutional standards. It was approved by the Ethics Committee of the Federal University of Bahia (Approval reference number 24/2006). This was a prospective cohort study conducted at the Federal University of Bahia Hospital in Salvador, Northeast Brazil (clinical trial on the use of amoxicillin, ClinicalTrials.gov Identifier NCT01200706). From November 2006 to April 2011 community-dwelling children were seen at the Pediatric Emergency Department and diagnosed by the pediatrician on duty with non-severe CAP. CAP diagnosis was based on 1) respiratory complaints (cough or difficulty breathing) plus 2) lower respiratory pathologic findings plus 3) presence of pulmonary infiltrate or consolidation on the chest radiograph (CXR) (frontal and lateral views) taken on admission and read by the pediatrician on duty. Non-severe CAP cases were defined according to the World Health Organization criteria for severity of CAP 2000 \[[@bib0030]\]. That means, eligible patients did not present any of the following items: lower chest indrawing, inability to drink, seizure, somnolence, central cyanosis, grunting in a calm child, and nasal flaring. The exclusion criteria comprised chronic debilitating diseases (anatomic abnormalities of the respiratory tract, cancer, chronic pulmonary illness besides asthma, immunological defects, progressing neurological disorders, psychomotor retardation, heart disease with clinical repercussion, hemoglobinopathy, liver or kidney disease, severe malnutrition), other concurrent infection, HIV-infected mother, hospitalization during the previous 7 days, amoxicillin or other antibiotics use during the last 48 h, amoxicillin allergy, or history of aspiration. The primary results of the clinical trial were published in 2014 \[[@bib0035]\].

Written informed consent was collected from parents or legal guardians before enrolment. Upon screening, demographic, clinical data and nasopharyngeal aspirate samples (NPA) were collected and a complete physical examination was performed by the research team. All data were registered in pre-defined questionnaires regarding the following variables: age, sex, disease duration, complaints (cough, fever, difficulty breathing, wheezing, vomiting), axillary temperature, respiratory rate (RR), weight, findings on physical examination (chest retraction, reduced pulmonary expansion, rhonchi, wheezing, crackles). Tachypnea was considered as RR ≥ 50 breaths/min in children aged 2--11 months or RR ≥ 40 breaths/min in children from 12 to 59 months of age \[[@bib0040]\]. Nutritional evaluation was performed using the software Anthro, version 1.02 (Centre for Disease Control and Prevention and WHO) and malnutrition and severe malnutrition were defined as Z-score for weight-for-age index under −2.00 or −3.00, respectively, using the National Centre for Health Statistics standard \[[@bib0045]\].

In order to perform a post hoc analysis regarding the radiographic findings, the CXR was sent to two independent pediatric radiologists who were blinded to clinical information. Radiographic reading was entered on a standardized form according to standardized interpretation \[[@bib0050]\]. Concordant radiologically-confirmed pneumonia was identified if there was agreement on the presence of pulmonary infiltrate or consolidation in the independent assessment by two radiologists. If there was disagreement between the initial radiologists, CXR was sent to a third pediatric radiologist who used the same methods. CXR reading was finally defined as agreed or not by two radiologists. All radiologists have worked primarily in pediatric radiology post completion of a two-year residency, with twenty, twenty-five, and thirty years of experience.

Immediately after collection, the NPA samples were stored at −80 °C at the Federal University of Bahia Hospital Laboratory until shipment to the University of Turku Clinical Virology Department, Turku, Finland, by airplane at −80 °C in dry ice. After thawing, a multiplex real-time PCR test kit (Anyplex \[TM\] II RV16, Seegene, Seoul, South Korea) \[[@bib0055]\] was performed to detect the following viruses: human adenovirus (HAdV), influenza A (Flu A) and B (Flu B) viruses, parainfluenza virus types 1--4 (PIV 1, PIV 2, PIV 3, PIV 4), rhinovirus (RV), respiratory syncytial viruses A (RSV A) and B (RSV B), human bocavirus 1 (HBoV1), coronaviruses 229E (HCoV 229E), NL63 (HCoV NL63), and OC43 (HCoV OC43), metapneumovirus (hMPV), and enteroviruses (EV) in NPA. The Anyplex (TM) II RV16 detection kit is a multiplex real-time PCR assay based on tagging oligonucleotide cleavage extension. Moreover, an in-house triplex PCR test was used to detect RV, EV, and RSV in NPA samples, as already reported \[[@bib0060]\]. Serious measures and surveillance were performed during the whole period of laboratory procedures in order to avoid PCR amplicon and sample-to-sample contamination.

For the descriptive part of the study, sample size was estimated to be 384 cases considering an expected frequency of respiratory virus of 50%, total width of confidence interval (CI) of 10%, and 95% confidence interval (95% CI). For the analytical part of the study, sample size was calculated considering the smaller expected frequency of 5%, an expected difference between the compared frequencies of 5%, power of 80%, and 2-tailed test with a significance level of 0.05. Thus, the sample size was estimated as 684 cases in the study group. We performed a bivariate analysis: the frequency of each respiratory virus was compared by using chi-square or Fisher's exact test as appropriate; continuous variables were presented as median (interquartile range \[IQR\]) and were assessed by using Mann-Whitney *U* test due to non-parametrical distribution. As the frequency of missing information was very low, we chose to handle the missing data by excluding the cases with missing information. All analyses were performed using the Statistical Package for the Social Sciences (SPSS), Version 9.0.

4. Results {#sec0020}
==========

A total of 820 children were recruited in the clinical trial. Seven hundred and seventy four children (94.4%) had NPA collected. Therefore, the study group consisted of 774 cases. A subgroup of 272 (36.4%) cases had concordant radiologically-confirmed pneumonia. According to radiologists 1, 2, and 3, consolidation was found in, respectively, 84.2%, 76.8%, and 69.1% of the 272 cases with concordant radiologically-confirmed pneumonia. As per each radiologist, the other cases presented pulmonary infiltrate. [Table 1](#tbl0005){ref-type="table"} presents the baseline characteristics of the study group.Table 1Baseline characteristics of children with non-severe community-acquired pneumonia.Table 1CharacteristicsAll CasesConcordant radiologically-confirmed pneumonia cases(n = 774) n (%)[a](#tblfn0005){ref-type="table-fn"}(n = 272) n (%)[a](#tblfn0005){ref-type="table-fn"}**Demographics** Age (median \[IQR\] months)25.5 (14.1--40.0)30.8 (18.3--44.4) Male gender411 (53.1)141 (51.8)  **History**Disease duration(median \[IQR\] days)5 (4--8)7 (4--10)Cough754/772[b](#tblfn0010){ref-type="table-fn"} (97.7)268/271[c](#tblfn0015){ref-type="table-fn"} (98.9)Fever715/773[b](#tblfn0010){ref-type="table-fn"} (92.5)262 (96.3)Difficulty breathing484/772[b](#tblfn0010){ref-type="table-fn"} (62.7)182/271[c](#tblfn0015){ref-type="table-fn"} (67.2)Vomiting346/773[b](#tblfn0010){ref-type="table-fn"} (44.8)119 (43.8)  **Physical examination**Rhonchi503/773[b](#tblfn0010){ref-type="table-fn"} (65.1)183 (67.3)Crackles349/773[b](#tblfn0010){ref-type="table-fn"} (45.1)151 (55.5)Tachypnea346/773[b](#tblfn0010){ref-type="table-fn"} (44.8)141 (51.8)Wheezing228/773[b](#tblfn0010){ref-type="table-fn"} (29.5)68 (25.0)Reduced pulmonary expansion66/772[b](#tblfn0010){ref-type="table-fn"} (8.5)45/271[c](#tblfn0015){ref-type="table-fn"} (16.6)Malnutrition29/773[b](#tblfn0010){ref-type="table-fn"} (3.8)7 (2.6)Chest retraction28/773[b](#tblfn0010){ref-type="table-fn"} (3.6)13 (4.8)[^1][^2][^3][^4]

All NPA samples were tested for 16 viruses. Viruses were detected from 708 (91.5%; 95% CI: 89.3%--93.3%) cases, out of which 491 (69.4%; 95% CI:65.9%--72.7%) were positive for multiple viruses. Among 272 cases with concordant radiologically-confirmed pneumonia, respiratory virus was detected in 238 (87.5%; 95% CI:83.2%--91.0%), out of which 170 (71.4%; 95% CI:65.4%--76.9%) had multiple viruses detected. When the baseline characteristics were compared, the only difference found was in the frequency of fever, which was more common among patients with multiple viruses in regard to patients with single virus (93.9% vs. 88.4%; P = 0.01). [Table 2](#tbl0010){ref-type="table"} presents the frequency of each respiratory virus detected. RV, HAdV, and EV were the most commonly found viruses either in the whole group or in the subgroup of patients with concordant radiologically-confirmed pneumonia. The in-house triplex PCR test and Anyplex II RV16 detected RV, EV, and RSV in 77.6% and 69.9% of the NPA samples, respectively. Data on acute HBoV1 infection diagnosed by serology have been published elsewhere \[[@bib0065]\].Table 2Frequency of respiratory viruses detected among children with non-severe CAP.Table 2All casesConcordant radiologically-confirmed pneumonia casesn = 774n = 272Virusesn (%; 95% CI)n (%; 95% CI)Rhinovirus357 (46.1; 42.6--49.6)128 (47.1;41.2--53.0)Adenovirus297 (38.4; 35.0--41.8)110 (40.4;34.7--46.4)Enterovirus205 (26.5; 23.5--29.7)85 (31.3;26.0--36.9)Respiratory Syncytial Viruses193 (24.9; 22.0--28.1)54 (19.9;15.4--24.9) RSV A109/763[a](#tblfn0020){ref-type="table-fn"} (14.3; 11.9--16.9)35/267[b](#tblfn0025){ref-type="table-fn"} (13.1;9.4--17.6) RSV B81/763[a](#tblfn0020){ref-type="table-fn"} (10.6; 8.6--13.0)16/267[b](#tblfn0025){ref-type="table-fn"} (6.0;3.6--9.3)Bocavirus174 (22.5; 19.6--25.5)72 (26.5;21.5--32.0)Parainfluenza viruses159 (20.5; 17.8--23.5)65 (23.9;19.1--29.2) PIV 131 (4.0; 2.8--5.6)11 (4.0;2.1--6.9) PIV 228 (3.6; 2.5--5.1)9 (3.3;1.6--6.0) PIV 368 (8.8; 6.9--10.9)29 (10.7;7.4--14.8) PIV 447 (6.1; 4.5--7.9)20 (7.4;4.7--10.9)Metapneumovirus100 (12.9; 10.7--15.4)31 (11.4;8.0--15.6)Influenza viruses66 (8.5; 6.7--10.7)15 (5.5;3.2--8.7) Flu A42 (5.4; 4.0--7.2)9 (3.3;1.6--6.0) Flu B26 (3.4; 2.3--4.8)6 (2.2;0.9--4.5)Coronaviruses64 (8.3; 6.5--10.4)16 (5.9;3.5--9.2) OC4343 (5.6; 4.1--7.3)12 (4.4;2.4--7.4) NL6316 (2.1; 1.2--3.3)3 (1.1;0.3--3.0) 229E13 (1.7; 0.9--2.8)2 (0.7;0.1--2.4)[^5][^6][^7]

Overall, among 491 cases with multiple virus detection, the number of detected viruses were: 2 (n = 234; 47.7%), 3 (n = 140; 28.5%), 4 (n = 66; 13.4%), 5 (n = 34; 6.9%), 6 (n = 13; 2.6%), 7 (n = 3; 0.6%), and 8 (n = 1; 0.2%), being RV plus HAdV (n = 177; 36.0%), RV plus HBoV1 (n = 108; 22.0%), EV plus HAdV (n = 90; 18.3%), EV plus RV (n = 85; 17.3%), and HBoV1 plus HAdV (n = 42; 8.6%) the most frequent combinations, either alone or along with other viruses. On the other hand, the number of detected viruses among 170 cases with concordant radiologically-confirmed pneumonia and multiple virus detections were: 2 (n = 75; 44.1%), 3 (n = 46; 27.1%), 4 (n = 28; 16.5%), 5 (n = 14; 8.2%), 6 (n = 5; 2.9%), and 7 (n = 2; 1.2%), being RV plus HAdV (n = 49; 28.8%), EV plus RV (n = 43; 25.3%), HBoV plus HAdV (n = 37; 21.8%), RV plus HBoV (n = 32; 18.8%), and EV plus HAdV (n = 30; 17.6%) the most frequent combinations, either alone or along with other viruses too.

[Table 3](#tbl0015){ref-type="table"} shows the comparison of the frequency of each virus among children with sole or multiple virus detection. In the whole group, no difference was found in the frequency of RSV A, RSV B, Flu A, Flu B, PIV 1, or PIV 4. Among 238 cases of non-severe CAP with concordant radiologically-confirmed pneumonia and virus detected, RV, HAdV, EV, HBoV1, and PIV 3 were significantly more frequent among cases with detection of multiple viruses. [Table 4](#tbl0020){ref-type="table"} compares the distribution of age and disease duration between children with or without each respiratory virus. Children with RSV A or PIV 3 or HCoV OC43 were younger than those without each one of them whereas children with PIV 4 were older than those without it. In regard to disease duration, children with RSV had a shorter disease than those without it. Similar results were found among patients with concordant radiologically-confirmed pneumonia. [Table 5](#tbl0025){ref-type="table"} presents the frequency of the baseline characteristics among patients with distinct respiratory viruses. [Table 6](#tbl0030){ref-type="table"} compares the baseline characteristics among patients with sole respiratory virus detection and detected distinct viruses. The frequency of fever, crackles and tachypnea was significantly different among the compared subgroups ([Table 6](#tbl0030){ref-type="table"}).Table 3Comparison of the frequency of each respiratory virus in children with sole or multiple virus detection among children with non-severe CAP and virus detected.Table 3Respiratory VirusesAll casesConcordant radiologically-confirmed pneumonia casesDetectionPDetectionPMultiple (n = 491)Sole (n = 217)Multiple (n = 170)Sole (n = 68)Rhinovirus302 (61.5)55 (25.3)\<0.001110 (64.7)18 (26.5)\<0.001Adenovirus272 (55.4)25 (11.5)\<0.001100 (58.8)10 (14.7)\<0.001Enterovirus201 (40.9)4 (1.8)\<0.00183 (48.8)2 (2.9)\<0.001Respiratory Syncytial Viruses131 (26.7)62 (28.6)0.641 (24.1)13 (19.1)0.4 RSV A78/485 (16.1)[a](#tblfn0030){ref-type="table-fn"}31/212 (14.6)[a](#tblfn0030){ref-type="table-fn"}0.629/167 (17.4)[a](#tblfn0030){ref-type="table-fn"}6/66 (9.1)[a](#tblfn0030){ref-type="table-fn"}0.1 RSV B53/485 (10.9)[a](#tblfn0030){ref-type="table-fn"}28/212 (13.2)[a](#tblfn0030){ref-type="table-fn"}0.410/167 (6.0)[a](#tblfn0030){ref-type="table-fn"}6/66 (9.1)[a](#tblfn0030){ref-type="table-fn"}0.4Bocavirus165 (33.6)9 (4.1)\<0.00168 (40.0)4 (5.9)\<0.001Parainfluenza viruses134 (27.3)25 (11.5)\<0.00157 (33.5)8 (11.8)0.001 PIV 125 (5.1)6 (2.8)0.29 (5.3)2 (2.9)0.7 PIV 226 (5.3)2 (0.9)0.0069 (5.3)00.06 PIV 360 (12.2)8 (3.7)\<0.00126 (15.3)3 (4.4)0.02 PIV 438 (7.7)9 (4.1)0.0817 (10.0)3 (4.4)0.2Metapneumovirus81 (16.5)19 (8.8)0.00624 (14.1)7 (10.3)0.4Influenza viruses51 (10.4)15 (6.9)0.112 (7.1)3 (4.4)0.6 Flu A31 (6.3)11 (5.1)0.56 (3.5)3 (4.4)0.7 Flu B22 (4.5)4 (1.8)0.096 (3.5)00.2Coronaviruses61 (12.4)3 (1.4)\<0.00113 (7.6)3 (4.4)0.6 OC4341 (8.4)2 (0.9)\<0.00110 (5.9)2 (2.9)0.5 NL6315 (3.1)1 (0.5)0.032 (1.2)1 (1.5)1 229E13 (2.6)--0.012 (1.2)01[^8]Table 4Comparison of age and disease duration among children with non-severe CAP with or without each respiratory virus.Table 4Respiratory virusMedian (IQR) age (months)Median (IQR) disease duration (days)Virus detectedVirus detectedYesNoPYesNoPRhinovirus WG26.6 (14.1; 41.3)24.1 (14.0; 39.1)0.25 (3; 10)5 (4; 8)0.7 CRCPSG32.4 (19.3; 45.9)28.8 (17.7; 42.8)0.37 (4; 12)7 (4; 10)0.6Adenovirus WG25.8 (15.1; 41.2)25.2 (13.5; 39.3)0.25 (3; 10)5.5 (4; 8)0.9 CRCPSG30.3 (19.1; 43.0)31.0 (16.7; 46.1)0.97 (4; 14)7 (4;10)0.8Enterovirus WG25.3 (15.4; 39.4)25.5 (13.6; 40.2)0.75 (4; 8)5 (4; 8)0.8 CRCPSG32.2 (17.6; 43.6)30.3 (18.4; 45.8)0.77 (4; 11)7 (4; 10)0.6Respiratory Syncytial Viruses WG24.0 (13.6; 35.6)26.4 (14.3; 42.0)0.025 (3; 7)6 (4; 10)\<0.001CRCPSG25.7 (15.9; 39.3)31.6 (18.9; 45.9)0.15 (4; 7)7 (4; 11)0.01 RSV A WG21.9 (13.5; 35.3)26.3 (14.3; 41.2)0.025 (3; 7)6 (4; 9)0.002CRCPSG24.3 (16.2; 40.9)31.2 (18.6; 44.8)0.35 (4; 7)7 (4; 10)0.04 RSV B WG25.2 (14.1; 36.0)25.6 (14.1; 40.9)0.55 (3; 7)6 (4; 8)0.005CRCPSG25.7 (17.0; 33.9)31.2 (18.4; 44.9)0.25 (3; 7)7 (4; 10)0.1Bocavirus WG26.1 (17.4; 38.1)25.1 (13.5; 40.8)0.46 (4; 11)5 (4; 8)0.1 CRCPSG26.8 (21.0; 40.0)31.3 (16.5; 46.2)0.67 (4; 15)7 (4; 10)0.3Parainfluenza viruses WG26.7 (14.3; 42.0)25.2 (13.8; 39.3)0.56 (4; 8)5 (4; 8)0.6CRCPSG32.5 (14.2; 46.3)30.3 (19.7; 44.0)0.87 (5; 10)7 (4; 10)0.9 PIV 1 WG39.1 (14.3; 44.2)25.2 (14.0; 39.6)0.16 (3; 7)5 (4; 8)0.5CRCPSG40.9 (12.4; 50.3)30.7 (18.4; 44.2)0.87 (5; 7)7 (4; 10)0.6 PIV 2 WG34.3 (19.4; 42.3)25.1 (13.8; 39.8)0.15 (3; 7)5 (4; 8)0.4CRCPSG36.0 (12.1; 41.9)30.7 (18.4; 44.8)0.65 (4; 11)7 (4; 10)0.4 PIV 3 WG18.7 (11.4; 30.8)26.3 (14.3; 40.4)0.016 (3.25; 10)5 (4; 8)0.5CRCPSG22.6 (11.0; 44.6)31.2 (19.2; 44.4)0.27 (5; 11)7 (4; 10)0.9 PIV 4 WG36.2 (15.2; 46.3)24.9 (13.9; 39.4)0.047 (5; 8)5 (4; 8)0.08CRCPSG41.0 (24.5; 52.7)29.4 (18.1; 43.8)0.047 (5; 10)7 (4; 10)0.5Metapneumovirus WG24.7 (13.3; 37.9)25.8 (14.1; 40.1)0.86 (4; 8)5 (4; 8)0.9 CRCPSG31.4 (22.7-50.4)30.7 (17.5; 44.3)0.27 (4; 10)7 (4; 10)0.9Influenza viruses WG27.0 (14.8; 37.8)25.1 (13.9; 40.2)0.65 (4; 7.25)5 (4; 8)0.5CRCPSG21.1 (11.4; 34.4)31.2 (18.4; 44.7)0.18 (7; 10)7 (4; 10)0.2 Flu A WG28.8 (14.8; 46.0)25.1 (13.9; 40.0)0.35 (3; 7.25)5 (4; 8)0.3CRCPSG23.7 (13.0; 34.6)30.9 (18.4; 44.6)0.38 (7; 12)7 (4; 10)0.3 Flu B WG24.6 (13.7; 37.2)25.5 (14.1; 40.2)0.65 (4; 7.5)5 (4; 8)0.9CRCPSG19.7 (8.2; 37.6)31.0 (18.4; 44.5)0.28 (5; 11)7 (4; 10)0.5Coronaviruses WG21.7 (12.3; 37.9)26.0 (14.1; 40.1)0.25 (4; 8)5 (4; 8)1CRCPSG35.9 (12.4; 44.0)30.5 (18.3; 44.6)0.97 (4; 10)7 (4; 10)0.9 OC43 WG20.9 (9.3; 34.6)26.1 (14.3; 40.3)0.027 (4; 10)5 (4; 8)0.4CRCPSG35.9 (8.6; 44.0)30.5 (18.4; 44.6)0.77 (5; 10)7 (4; 10)0.6 NL63 WG27.3 (15.4; 50.1)25.5 (13.9; 39.7)0.35 (3.25; 7)5 (4; 8)0.2CRCPSG41.2 (21.7; 56.0)30.7 (18.2; 44.4)0.43 (1; 10)7 (4; 10)0.2 229E WG29.7 (14.9; 47.5)25.5 (14.0; 39.9)0.65 (4; 8)5 (4; 8)0.9CRCPSG33.4 (22.5; 44.4)30.8 (18.3; 44.5)0.87 (4; 9)7 (4; 10)0.9[^9][^10]Table 5Frequency of baseline characteristics among patients with non-severe community-acquired pneumonia and distinct respiratory viruses.Table 5CharacteristicsRespiratory viruses detectedRhinovirus n = 357Adenovirus n = 297Enterovirus n = 205RSV n = 193RSV A n = 109RSV B n = 81Bocavirus N = 174**Demographics** Male gender196 (54.9)160 (53.9)114 (55.6)112 (58.0)67 (61.5)47 (58.0)98 (56.3)  **History**Cough344/356 (96.6)286/296 (96.6)198/204 (97.1)191 (99.0)108 (99.1)80 (98.8)170 (97.7)Fever316 (88.5)277 (93.3)194 (94.6)183 (94.8)102 (93.6)78 (96.3)166 (95.4)Difficulty breathing219/356 (61.5)174/296 (58.8)128/204 (62.7)136 (70.5)77 (70.6)53 (65.4)113 (64.9)Vomiting151 (42.3)136 (45.8)90 (43.9)94 (48.7)56 (51.4)37 (45.7)75 (43.1)  **Physical examination**Rhonchi234 (65.5)186 (62.6)129 (62.9)121 (62.7)69 (63.3)47 (58.0)109 (62.6)Crackles156 (43.7)125 (42.1)98 (47.8)95 (49.2)55 (50.5)35 (43.2)83 (47.7)Tachypnea144 (40.3)115 (38.7)84 (41.0)108 (56.0)63 (57.8)40 (49.4)73 (42.0)Wheezing109 (30.3)77 (25.9)61 (29.8)68 (35.2)42 (38.5)25 (30.9)46 (26.4)Reduced pulmonary expansion34 (9.5)26/296 (91.2)20 (9.8)9/192 (4.7)9/108 (8.3)018 (10.3)Malnutrition14 (3.9)15 (5.1)8 (3.9)5 (2.6)3 (2.8)2 (2.5)3 (1.7)Chest retraction12 (3.4)12 (4.9)10 (4.9)8 (4.1)6 (5.5)3 (3.7)6 (3.4)CharacteristicsRespiratory viruses detectedParainfluenza n = 159PIV 1 n = 31PIV 2 n = 28PIV 3 n = 68PIV 4 n = 47Metapneumovirus n = 100**Demographics** Male gender84 (52.8)15 (48.4)15 (53.6)39 (57.4)23 (48.9)51 (51.0)  **History**Cough157 (98.7)31 (100.0)27 (96.4)68 (100.0)46 (97.9)98/99 (99.0)Fever149 (93.7)30 (96.8)28 (100.0)64 (94.1)42 (89.4)96/99 (97.0)Difficulty breathing98 (61.6)19 (61.3)15 (53.6)43 (63.2)27 (57.4)61/99 (61.6)Vomiting72 (45.3)10 (32.3)11 (39.3)33 (48.5)25 (53.2)49/99 (49.5)  **Physical examination**Rhonchi118 (74.2)24 (77.4)20 (71.4)52 (76.5)34 (72.3)63/99 (63.6)Crackles69 (43.4)10 (32.3)11 (39.3)36 (52.9)19 (40.4)54/99 (54.5)Tachypnea65 (40.9)12 (38.7)14 (50.0)30 (44.1)14 (29.8)55/99 (55.6)Wheezing44 (27.7)8 (25.8)4 (14.3)17 (25.0)16 (34.0)34/99 (34.3)Reduced pulmonary expansion12 (7.5)3 (9.7)1 (3.6)5 (7.4)3 (6.4)9/99 (9.1)Malnutrition6 (3.8)2 (6.5)02 (2.9)3 (6.4)6/99 (6.1)Chest retraction6 (3.8)003 (4.4)3 (6.4)6/99 (6.1)CharacteristicsRespiratory viruses detectedInfluenza\
n = 66Flu A\
n = 42Flu B\
n = 26Coronavirus\
n = 64OC43\
n = 43NL63\
n = 16229E\
N = 13**Demographics** Male gender37 (56.1)24 (57.1)15 (57.7)28 (43.8)18 (41.9)8 (50.0)3 (23.1)  **History**Cough61 (92.4)38 (90.5)25 (96.2)61 (95.3)42 (97.7)15 (93.8)12 (92.3)Fever64 (97.0)41 (97.6)24 (92.3)59 (92.2)42 (97.7)14 (87.5)11 (84.6)Difficulty breathing36 (54.5)20 (47.6)16 (61.5)38 (59.4)24 (55.8)10 (62.5)7 (53.8)Vomiting30 (45.5)18 (42.9)12 (46.2)25 (39.1)18 (41.9)6 (37.5)7 (53.8)  **Physical examination**Rhonchi41 (62.1)25 (59.5)18 (30.8)39 (60.9)26 (60.5)10 (62.5)9 (69.2)Crackles29 (43.9)19 (45.2)10 (38.5)19 (29.7)13 (30.2)4 (25.0)2 (15.4)Tachypnea24 (36.4)15 (35.7)9 (34.6)28 (43.8)21 (48.8)8 (50.0)6 (46.2)Wheezing17 (25.8)11 (26.2)7 (26.9)20 (31.3)15 (34.9)4 (25.0)4 (30.8)Reduced pulmonary expansion4 (6.1)3 (7.1)1 (3.8)3 (4.7)3 (7.0)01 (7.7)Malnutrition2 (3.0)1 (2.4)1 (3.8)4 (6.3)4 (9.3)00Chest retraction2 (3.0)2 (4.8)03 (4.7)2 (4.7)2 (12.5)2 (15.4)[^11]Table 6Comparison of baseline characteristics among patients with non-severe community-acquired pneumonia and sole virus detection.Table 6CharacteristicsRespiratory viruses detectedRhinovirus\
n = 55Adenovirus\
n = 25Enterovirus\
n = 4RSV\
n = 62Bocavirus\
n = 9Parainfluenza\
n = 25Metapneumovirus\
N = 19\*\*jha**Demographics** Male gender32 (58.2)11 (44.0)1 (25.0)32 (51.6)4 (44.4)15 (60.0)12 (63.2)  **History**Cough53 (96.4)23 (92.0)4 (100.0)62 (100.0)9 (100.0)25 (100.0)18/18 (100.0)Fever41 (74.5)22 (88.0)4 (100.0)57 (91.9)9 (100.0)23 (92.0)17/18 (94.4)Difficulty breathing39 (70.9)14 (56.0)3 (75.0)48 (77.4)6 (66.7)14 (56.0)13/18 (72.2)Vomiting22 (40.0)13 (52.0)2 (50.0)36 (58.1)3 (33.3)12 (48.0)9/18 (50.0)  **Physical examination**Rhonchi42 (76.4)16 (64.0)1 (25.0)41 (66.1)6 (66.7)20 (80.0)9/18 (50.0)Crackles27 (49.1)5 (20.0)3 (75.0)34 (54.8)6 (66.7)5 (20.0)14/18 (77.8)Tachypnea25 (45.5)6 (24.0)2 (50.0)40 (64.5)5 (55.6)9 (36.0)11/18 (61.1)Wheezing17 (30.9)4 (16.0)1 (25.0)25 (40.3)5 (55.6)5 (20.0)9/18 (50.0)Reduced pulmonary expansion7 (12.7)3 (12.0)02 (3.2)01 (4.0)3/18 (16.7)Malnutrition1 (1.8)1 (4.0)01 (1.6)02 (8.0)1/18 (5.6)Chest retraction2 (3.6)1 (4.0)03 (4.8)1 (11.1)2 (8.0)1/18 (5.6)CharacteristicsRespiratory viruses detectedPInfluenza\
n = 15Coronavirus\
n = 3**Demographics** Male gender7 (46.7)2 (66.7)0.8  **History**Cough13 (86.7)3 (100.0)0.1Fever15 (100.0)3 (100.0)0.04Difficulty breathing6 (40.0)2 (66.7)0.2Vomiting5 (33.3)1 (33.3)0.6  **Physical examination**Rhonchi8 (53.3)2 (66.7)0.2Crackles7 (46.7)0\<0.001Tachypnea4 (26.7)00.007Wheezing4 (26.7)1 (33.3)0.2Reduced pulmonary expansion1 (6.7)1 (33.3)0.3Malnutrition1 (6.7)1 (33.3)0.2Chest retraction000.9[^12]

5. Discussion {#sec0025}
=============

We detected respiratory viruses in 91.5% of all cases out of which multiple viruses were detected in 69.4%. RV, HAdV, and EV were the most frequently found viruses. RSV, Flu A, Flu B, PIV 1, and PIV 4 were similarly found among cases with multiple or sole detection. Children with RSV A, PIV 3, or HCoV OC43 were younger than those without each one of them whereas children with PIV 4 were older than those without it. Children with RSV had shorter disease length than those without it.

To our knowledge, our viral detection rates are the highest ones reported so far in children with CAP. A recently published study conducted in Sweden found respiratory viruses in 81% of children aged under 5 years hospitalized with CAP \[[@bib0070]\]. Another study conducted in Spain detected respiratory viruses in 83% of children aged under 18 months hospitalized with CAP \[[@bib0075]\]. Both studies employed PCR to search for the respiratory viruses in NPA: in the Swedish study, single agent and duplex real-time PCRs and in the Spanish study, multiplex PCR assay. It has been previously reported that the detection rate of singleplex PCR is higher when compared to the multiplex one showing that the singleplex PCR is more sensitive than the multiplex PCR for the specific virus \[[@bib0080]\]. However, combination of multiplex PCR tests can provide a 100% recovery rate \[[@bib0085]\]. Therefore, we attribute our high detection rate to the employment of both triplex and multiplex PCRs in this study.

The most frequently detected viruses were RV, HAdV, and EV. RV was also the most commonly detected virus among 76 children aged 6 months to 15 years hospitalized for CAP in Turku, Finland \[[@bib0090]\]. As opposed to what was pointed out by Pavia \[[@bib0095]\], EV was commonly found in our study and this can be explained by our use of two different PCR techniques to search for it. In fact, this can also explain the high rate of RV detection that, in our study, was the most frequently detected virus unlike previously published studies which showed RSV to have the highest detection rate \[[@bib0070],[@bib0075]\]. We employed an in-house triplex PCR to search for RV, EV, and RSV besides the multiplex PCR that also investigated the presence of these three viruses along with the other 13 respiratory viruses. Notably, the pathogenic role of RV has been recently described in adults with CAP, with a more modest association in older children (5--17 years old) \[[@bib0100]\]. Additionally, RV was identified as one of the major microorganisms associated with CAP in children \<5 years of age from developing and emerging countries hospitalized with CAP in a multicenter case-control study \[[@bib0105]\].

The clinical significance of multiple respiratory virus detection causing childhood CAP is not completely clear. Recently published reports have concluded that there is no association between multiple respiratory virus detection and disease severity \[[@bib0110],[@bib0115]\]. In our study, multiple viruses were detected in approximately 70% of the cases with virus-positive cases with non-severe CAP, which, to the best of our knowledge, is the highest co-detection rate reported so far. Therefore, we conclude that, mainly due to the fact that all of our cases had non-severe CAP, viral co-detection is not related to disease severity. However, it was possible to observe that fever was significantly more frequent among cases with multiple viruses.

Recently, it was demonstrated that Flu and RSV showed a positive association with childhood CAP in a case-control study \[[@bib0070]\]. In our study, Flu A and B, RSV A and B, as well as PIV 1 and PIV 4, were similarly found in cases with sole or multiple virus detection whereas the other respiratory viruses were more common in cases with multiple virus detections ([Table 3](#tbl0015){ref-type="table"}). As a matter of fact, multiple virus detection can comprise past infection, symptomatic infection, or even upcoming infection. The role of each virus found in multiple virus detection is a very complex issue. Herein, HBoV1 was more frequently found in multiple then in sole virus detection ([Table 3](#tbl0015){ref-type="table"}). However, we have demonstrated that acute serologically diagnosed HBoV1 infection occurred in 22.5% of cases with multiple virus detection, as well as in 50.0% of cases with sole virus detection \[[@bib0065]\]. The challenge is to show causativeness. Effect-cause is often a problem in cross-sectional and case-control studies, especially when the predictor variable is a laboratory test; even in cohort studies, effect-cause is difficult to be shown if the disease has a long latent period \[[@bib0120]\]. In terms of lung infection like CAP, the ideal investigation should comprise lung tap \[[@bib0125]\]. Nonetheless, for ethical reasons, lung specimens are rarely obtained, so NPA are used to infer what is infecting the lung. Many of the same pathogens present in NPA can also cause CAP, might be involved in the causal chain of CAP, or might represent a concurrent upper respiratory tract infection or colonization unrelated to the pneumonic process \[[@bib0130]\]. That is why serology is a potential tool to clarify this issue \[[@bib0135]\].

In regard to age, RSVA, PIV3 and HCoV OC43 were significantly more frequent in younger patients whereas PIV4 was significantly more common in older cases ([Table 4](#tbl0020){ref-type="table"}). RSV is a paramyxovirus that has been widely detected in children with CAP. The incidence and severity varies with age and younger children have been described as the more generally infected \[[@bib0095]\]. However, it has also been reported that RSV infection in younger children are more severe than in older ones \[[@bib0095]\]. Interestingly, all of our cases had non-severe CAP and RSVA was found in younger cases and in cases with shorter duration of disease. These findings demonstrate the wide presentation of RSV infection in children and may be useful in the implementation of the upcoming vaccines for the prevention of RSV infection in children \[[@bib0140]\] prioritized by age stratum. Noteworthily, all patients with enterovirus, bocavirus, influenza, or coronavirus reported fever whereas 3 quarters of the patients with rhinovirus reported it ([Table 6](#tbl0030){ref-type="table"}; P = 0.04). Additionally, none of the patients with coronavirus had crackles nor tachypnea, whereas 77.8% and 61.1% of the patients with metapneumovirus had crackles and tachypnea, respectively ([Table 6](#tbl0030){ref-type="table"}; P \< 0.001 and 0.007, respectively). Thus, it is possible to infer that there is some variation in the presentation of the illness caused by distinct viruses.

Besides the fact that our recruitment period lasted almost 4 and a half years, reducing the chances of bias regarding viral seasonality, our study has a major strength in enrolling a high number of cases, 820, out of which 94.4% had NPA samples collected, diagnosed by standardized criteria employed in clinical practice, increasing in this way the power and the external validity of the study. Therefore, our results may truly describe the frequency of respiratory viruses, as well as suggest the importance of each respiratory virus in children with non-severe CAP.

The main limitation of our study is the absence of healthy controls. However, respiratory virus detection has been reported in approximately 50% of asymptomatic subjects in the same age stratum as our cases \[[@bib0070],[@bib0105]\]. This, in turn, reinforces the importance of respiratory viruses in children with non-severe CAP, as our detection rate was approximately 90%.

In conclusion, our study indicates that respiratory viruses are massively found in cases with non-severe CAP, being multiple viruses detected in the majority of them.
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[^1]: IQR, interquartile range.

[^2]: Expressed as absolute number and percentage if not otherwise specified.

[^3]: The denominator was not 774 because there was missing information.

[^4]: The denominator was not 272 because there was missing information.

[^5]: CAP, community-acquired pneumonia; CI, confidence interval.

[^6]: The denominator was not 774 because there was missing information.

[^7]: The denominator was not 272 because there was missing information.

[^8]: Different denominator from the whole subgroup due to missing data on RSV subtype.

[^9]: WG, whole group (774 cases).

[^10]: CRCPSG, concordant radiologically-confirmed pneumonia subgroup (272 cases).

[^11]: Results are expressed as absolute number and percentage.

[^12]: Results are expressed as absolute number and percentage.
